Synaptic mitochondrial dysfunction and Alzheimer’s disease: from molecular mechanisms to therapeutic strategies
The ability of AD treatments targeting classic pathological proteins to achieve meaningful clinical outcomes has been severely limited, shifting attention to the earlier upstream pathways that drive disease progression. Increasing evidence indicates that synaptic mitochondrial dysfunction is an earl...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Frontiers Media S.A.
2026-09-01
|
| Sraith: | Frontiers in Pharmacology |
| Ábhair: | |
| Rochtain ar líne: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1849218/full |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|